Malignancy-Associated Hemophagocytic Lymphohistiocytosis: An Aggressive Entity Which Requires Early Diagnosis

Nahla AM Hamed
Additional contact information
Nahla AM Hamed: Professor of Clinical Hematology, Faculty of Medicine, Alexandria University, Egypt

Cancer Therapy & Oncology International Journal, 2019, vol. 13, issue 2, 55-58

Abstract: HLH comprises two main groups: malignancy-associated HLH (or M-HLH) and non-malignancy associated HLH. Treatment of HLH depends on the severity of the presentation as well as the underlying cause. M-HLH is an important subgroup of HLH because its prognosis is dismal.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555856.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555856.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:13:y:2019:i:2:p:55-58

DOI: 10.19080/CTOIJ.2019.13.555856

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().